INmune Bio Inc. (NASDAQ: INMB) announced that results from its Phase 2 MINDFuL trial evaluating XPro1595 in Alzheimer's disease patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE